Target Raises Earnings Guidance as 2Q Profit Tops Street Views
By Colin Kellaher
Target posted a fiscal second-quarter profit that blew past Wall Street's expectations and raised its full-year earnings guidance.
The Minneapolis retailer on Wednesday reported earnings of $1.19 billion, or $2.57 a share, for the quarter ended Aug. 3, up from $835 million, or $1.80 a share, a year earlier, and ahead of the $2.18 a share that analysts polled by FactSet, on average, were expecting.
Revenue rose 2.7% to $25.45 billion, ahead of the $25.19 billion Wall Street was looking for, while comparable sales rose 2%, topping the 1.1% rise analysts had penciled in.
Target lifted its full fiscal-year earnings guidance to $9.00 to $9.70 from a prior forecast of $8.60 to $9.60 a share and backed its comparable-sales guidance of flat to up 2%, although the retailer said growth will more likely be in the lower half of that range. Wall Street is expecting a full-year profit of $9.23 a share and a 0.1% rise in comparable sales, according to FactSet.
Target said it expects third-quarter earnings of $2.10 to $2.40 a share, with comparable sales flat to up 2%. Analysts are expecting a profit of $2.22 a share amid a 1.5% rise in comparable sales, according to FactSet.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
August 21, 2024 06:45 ET (10:45 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks